Online pharmacy Capsule plans to expand beyond New York City

Capsule Corp., a New York City-based online pharmacy startup, plans to expand to other large cities after raising $200 million, according to Bloomberg.

Advertisement

Capsule’s online platform allows patients to get prescription drugs delivered to them within two hours, offers easily-digestible information on copayst and and lets patients ask pharmacists questions over the phone, on the web or via an app.

Physicians are able to set up refill preferences through the app and also have the ability to choose alternate drugs for patients whose insurance may not cover certain drugs.

Capsule currently has 60,000 users in New York City.

Eric Kinariwala, founder and CEO of Capsule, told Bloomberg that Capsule is in the process of applying for pharmacy licenses in additional states and that it will be available in all major cities within the next 18 to 36 months.

This comes as major retail pharmacies, like CVS, are expanding their delivery options and other services to compete with startups like Capsule.

More articles on pharmacy:

Florida compounding facility recalls all human and animal drugs for lack of sterility

Despite ‘Right-to-try’ law, drugmakers still prefer FDA review, GAO finds

Opioid settlements may mean big tax breaks for Big Pharma

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.